Axol Bioscience Ltd. is a biotechnology company based in Little Chesterford, United Kingdom, specializing in human cell culture systems and custom services for disease modeling and drug discovery. The company produces a variety of human cells, including induced pluripotent stem cell (iPSC)-derived cells such as cardiomyocytes, neural stem cells, and dopaminergic neuron progenitors, as well as primary cells like endothelial and muscle cells. In addition to cell products, Axol offers critical reagents, including cell culture media, coating solutions, and growth factors. The company provides services such as iPSC reprogramming, differentiation, genome editing, and custom cell sourcing, catering to researchers who wish to utilize patient-derived samples. Axol's offerings also encompass disease models for conditions like Alzheimer's and Parkinson's diseases. Its products and services are distributed internationally, reaching markets in North America, Europe, and Asia. Incorporating a commitment to innovation, Axol operates from the Chesterford Research Park in Cambridge, UK, since its incorporation in 2012.